Multimodality Treatment for Metastatic Lung Cancer that Includes Surgery May Improve Survival Rates

Surgery may benefit select group of patients; multidisciplinary evaluation is critical to success

Chicago, June 10, 2015

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.  

Key points

  • Patients diagnosed with stage IIIB NSCLC may benefit from multimodality treatment that combines surgical resection in combination with chemotherapy or radiation therapy.
  • Surgery should be added to the treatment regimen only for carefully selected patients.
  • The researchers said multidisciplinary evaluation of patients is critical to successful treatment, and more research needs to be conducted before definitive guidelines can be established.

“Currently, most patients with stage IIIB non-small cell lung cancer are not candidates for surgery; instead, they are treated with chemotherapy and radiation only,” said Matthew J. Bott, MD, from Washington University in St. Louis, who led the study.

In stage IIIB NSCLC, the tumor usually has spread to lymph nodes or invaded other organs around the lungs, such as the heart, esophagus, or trachea. Patients with stage IIIB NSCLC have a 5-year overall survival rate of only 10%.

Dr. Bott and colleagues evaluated data from the National Cancer Database on 9,173 patients with stage IIIB NSCLC who had undergone combination treatment (multimodality therapy) between 1998 and 2010.

Patients were split into two groups: 7,459 patients who were treated with combined chemotherapy and radiation (CR group), and 1,714 patients who were treated with chemotherapy, radiation, and surgery (CRS group) in any order.

The researchers found that the median overall survival was more than 9 months longer in the CRS group than in the CR group (25.9 months vs. 16.3 months, respectively).

Because the patients in the CRS group tended to be younger, Caucasian, and have slightly smaller tumors than the patients in the CR group, Dr. Bott cautioned that surgery should be added to the treatment regimen only for carefully selected patients and that more research needs to be conducted before definitive guidelines can be established.

“We hope that our research reinvigorates discussion regarding the optimal treatment of these patients and leads to greater multidisciplinary evaluation of treatment options, with increased participation of thoracic surgeons in the decision-making process,” said Dr. Bott.  


Notes for editors
Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non–Small Cell Lung Cancer
doi:10.1016/j.athoracsur.2015.02.033 The Annals of Thoracic Surgery published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact Cassie McNulty at +1 312 202 5865

About The Annals of Thoracic Surgery
The Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association. Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,800 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Cassie McNulty
Media Relations Manager STS
+1 312 202 5865